MDxHealth suspends 2026 guidance after sales force disruption

The urology diagnostics company reported flat Q3 revenue of $22.7m and withdrew its $110–115m full-year target following unexpected sales team attrition.

The Biotech Times Editorial Team By The Biotech Times Editorial Team AI level 2 of 5
AI level 2 of 5: drafted by our AI editorial assistant from the company's announcement; fact-checked, edited and signed off by Mark Walker, Editorial Director. What the levels mean
A brightly lit dialysis machine with attached tubing and IV bags stands in a clinic room, with an IV pole and a comfortable recliner chair visible in the background.

MDxHealth has suspended its full-year 2026 revenue guidance of $110–115 million after a weaker-than-expected third quarter, citing unexpected sales force turnover that the company says disrupted its commercial execution rather than any structural change in clinical demand.

Preliminary unaudited revenue from continuing operations for the quarter ended 30 September 2026 came in at approximately $22.7 million, flat against $22.7 million in the same period a year earlier. The prior-year figure has been restated to exclude Resolve mdx, which is now carried as a discontinued operation. Cash and cash equivalents stood at roughly $31.7 million at the quarter's close.

Test volume diverges by product line

The flat revenue figure masks contrasting trends across MDxHealth's two product categories. Tissue-based test volume, covering the Confirm mdx and GPS mdx assays used in prostate cancer diagnosis and prognosis, fell 11% year-on-year to 11,232 tests. Liquid-based volume under the Exo mdx platform reached 11,792, up sharply from 4,600 in the prior-year period, a comparison that reflects the September 2025 acquisition of the ExoDx and GPS prostate cancer businesses.

Chief executive Michael McGarrity attributed the Q3 shortfall directly to sales force attrition following the discontinuation of Resolve mdx. "We experienced unexpected turnover within our sales force catalysed by aggressive targeting from recruiters," he said, adding that the company does not believe the disruption reflects any change in customer relationships or underlying clinical demand. McGarrity said full corrective-action detail will be provided alongside the complete Q3 results and an earnings call on 12 November 2026.

Market context and competitive pressures

MDxHealth operates in the urology precision diagnostics segment, a space that has drawn sustained commercial interest given the high volume of prostate cancer diagnoses and ongoing clinical debate around active surveillance versus treatment. The GPS mdx test competes with a small number of validated genomic risk-stratification assays, and payer coverage decisions remain a material variable for companies in this segment. Reimbursement policy shifts by US commercial insurers and Medicare Administrative Contractors have historically driven quarter-to-quarter volatility in test volumes across the sector.

The company's guidance withdrawal is notable because it follows three years in which MDxHealth's management explicitly cited its disciplined forecasting process as a differentiator. A flat quarter against a restated baseline, combined with a double-digit tissue-based volume decline, will raise questions among investors about how quickly the sales territories can be restabilised and whether the liquid-based volume trajectory is sufficient to offset continuing softness in the tissue-based book.

Investors will be watching the 12 November earnings call for updated territory coverage metrics, any revised outlook for full-year 2026, and early indications of Q4 momentum as the company works to recover commercial ground before year-end.

Sector

Topic

Geography